The World Health Organization (WHO) today approved the Nuvaxovid vaccine developed by the US pharmaceutical company Novavax as the 10th new coronavirus pneumonia (COVID-19) vaccine on the WHO Emergency Use List (EUL).
The European Commission (European Commission) accepted the European Medicines Agency (EMA) recommendation on December 20 to approve Nuvaxovid for people 18 years of age or older, which is the fifth vaccine approved by the European Union.
The picture shows the European Medicines Agency in Amsterdam, Netherlands, under the lens on April 20, 2021.
Amstel, the Netherlands is the resident of the European Medicines Agency.
(AP)
The other nine COVID-19 vaccines on the WHO emergency use list include the Covovax vaccine approved on the 17th, which is another version of the vaccine produced by the Serum Institute of India licensed by Novavax.
The vaccines on the list also include Fubitai vaccine (a joint research and development by Pfizer Pfizer in the United States and BioNTech, a German biotech company), Moderna, Johnson & Johnson, and AstraZeneca (2 vaccines in Europe). The Indian version and the Indian version count as 1 each), India’s Covaxin, and China’s Sinopharm and Coxing.
The picture shows the sign outside the headquarters of the American pharmaceutical company Novavax in Maryland on November 30, 2020.
(Reuters)
According to the results of two large-scale clinical trials involving more than 45,000 people in the United Kingdom and the United States and Mexico, Nuvaxovid is approximately 90% effective in preventing symptomatic cases.
New crown pneumonia|The Indian version of Novavax is listed as the 9th vaccine in the WHO emergency use list. New crown pneumonia| Novavax in the United States: Taiwan purchased the new crown vaccine through COVAX|The overall effective rate of Novavax in the United States is 90 %
In another document, the WHO Strategic Advisory Group of Experts on Immunisation recommended that Nuvaxovid can be opened to people over 18 years of age, with an interval of 3 to 4 weeks between the two doses.
